Mirae Asset Global Investments Co. Ltd. Has $339,000 Position in Replimune Group, Inc. (NASDAQ:REPL)

Mirae Asset Global Investments Co. Ltd. increased its position in shares of Replimune Group, Inc. (NASDAQ:REPL) by 32.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 40,223 shares of the company’s stock after purchasing an additional 9,859 shares during the period. Mirae Asset Global Investments Co. Ltd. owned approximately 0.07% of Replimune Group worth $339,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. increased its stake in Replimune Group by 352.8% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,833 shares of the company’s stock worth $58,000 after acquiring an additional 5,324 shares during the period. Harbor Capital Advisors Inc. raised its holdings in Replimune Group by 6.1% in the 4th quarter. Harbor Capital Advisors Inc. now owns 32,311 shares of the company’s stock valued at $272,000 after acquiring an additional 1,844 shares in the last quarter. Exchange Traded Concepts LLC raised its holdings in Replimune Group by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 7,837 shares of the company’s stock valued at $66,000 after acquiring an additional 1,988 shares in the last quarter. Vanguard Group Inc. raised its holdings in Replimune Group by 10.3% in the 3rd quarter. Vanguard Group Inc. now owns 2,596,119 shares of the company’s stock valued at $44,420,000 after acquiring an additional 242,220 shares in the last quarter. Finally, Wellington Management Group LLP raised its holdings in Replimune Group by 25.2% in the 3rd quarter. Wellington Management Group LLP now owns 261,277 shares of the company’s stock valued at $4,470,000 after acquiring an additional 52,633 shares in the last quarter. 92.53% of the stock is owned by institutional investors and hedge funds.

Replimune Group Price Performance

Shares of NASDAQ REPL opened at $6.42 on Friday. The stock has a market capitalization of $394.12 million, a PE ratio of -2.03 and a beta of 1.21. The company has a debt-to-equity ratio of 0.16, a current ratio of 12.40 and a quick ratio of 12.40. The business has a fifty day moving average price of $7.83 and a two-hundred day moving average price of $9.16. Replimune Group, Inc. has a fifty-two week low of $5.86 and a fifty-two week high of $24.81.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Thursday, February 8th. The company reported ($0.77) earnings per share for the quarter, beating the consensus estimate of ($0.89) by $0.12. As a group, equities analysts predict that Replimune Group, Inc. will post -3.28 earnings per share for the current fiscal year.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.